Skip to content
value.today

NovaBridge Biosciences

NBP
$177 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-46 M
SEC filing
Employees
228
As on 2020
value.today research

NovaBridge Biosciences in brief

NovaBridge Biosciences is a listed company in the Biotechnology industry, based in China. Its last known market value was $177 M (January 2024); there is no current figure. It employs about 228 people. Its shares trade under the symbol NBP (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About NovaBridge Biosciences

I-Mab is a Clinical Stage Biopharmaceutical company. It is committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company annual revenue is 114.5 million USD. The headquarters is in China.

NovaBridge Biosciences timeline

1 events, 2020
  1. 2020
  2. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of NovaBridge Biosciences from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$897 M$1.8 B$2.7 B$3.6 B2021202220232024

World rank over time

▼ down 14,531 places since 2021
2021-01-01: #4016#4,01620212022-01-07: #4633#4,63320222022-12-25: #15966#15,96620222023-07-30: #17106#17,10620232024-01-05: #18547#18,5472024

Rank in China: #786 (Jan 2021) · #988 (Jan 2022) · #4,528 (Dec 2022) · #4,813 (Jul 2023) · #4,978 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-20.0%
Liabilities / assets
11.4%
Revenue growth
-95.4%
R&D / revenue
3404.8%
Profit per employee
$-203 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $2M, net income $-44M$2MFY17Fiscal year ending Dec 2019: revenue $4M, net income $-209M$4MFY19Fiscal year ending Dec 2020: revenue $236M, net income $72M$236MFY20Fiscal year ending Dec 2021: revenue $14M, net income $-366M$14MFY21Fiscal year ending Dec 2022: revenue —, net income $-371M—FY22Fiscal year ending Dec 2023: revenue $1M, net income $-208M$1MFY23Fiscal year ending Dec 2024: revenue —, net income $-22M—FY24Fiscal year ending Dec 2025: revenue —, net income $-46M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-94M$-46M—
Dec 2024——$-51M$-22M—
Dec 2023$1M—$-72M$-208M-32973.0%
Dec 2022——$-53M$-371M—
Dec 2021$14M-94.2%—$-366M-2649.3%
Dec 2020$236M+5385.4%—$72M30.5%
Dec 2019$4M+152.0%—$-209M-4839.0%
Dec 2017$2M——$-44M-2580.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-21M$0M$-21M$-0.21—
Dec 2024$-53M$0M$-53M$-0.12—
Dec 2023$-184M$0M$-184M$-1.09—
Dec 2022$-160M$2M$-162M$-1.96—
Dec 2021$-153M$5M$-157M$-2.09—
Dec 2020$66M$1M$65M$0.46—
Dec 2019$-125M$2M$-126M$-28.90—
Dec 2017$-37M$3M$-40M$-7.68—

Annual results

Revenue
—
Operating income
$-94 M
Net income
$-46 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$261 M
Total liabilities
$30 M
Total equity
$231 M

As of December-2025

Top 48 institutional investors in NovaBridge Biosciences#

As of Sep 30, 2026
48 institutions held 22.8 M shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in NovaBridge Biosciences
#InstitutionShares heldChange (shares)ValueFiled
1Hhlr Advisors, LTD.5,980,5680 (0.00%)$8 MNov 16, 2026
2Morgan Stanley3,471,552-181,676 (-4.97%)$5 MNov 13, 2026
3AIHC Capital Management Ltd2,878,0330 (0.00%)$4 MNov 16, 2026
4Citadel Advisors LLC1,381,516+758,685 (+121.81%)$2 MNov 16, 2026
5Candriam S.C.A.1,132,5630 (0.00%)$2 MNov 3, 2026
6Adage Capital Partners GP, L.L.C.1,000,0000 (0.00%)$1 MNov 16, 2026
7Two Sigma Investments, LP874,250+22,902 (+2.69%)$1 MNov 16, 2026
8BlackRock, Inc.749,282+63,074 (+9.19%)$1 MNov 13, 2026
9Marshall Wace, LLP727,345-504,601 (-40.96%)$1 MNov 13, 2026
10UBS Group AG689,762+387,982 (+128.56%)$1 MNov 10, 2026
11Exome Asset Management LLC576,9600 (0.00%)$1 MNov 16, 2026
12Diadema Partners LP500,000New$1 MNov 16, 2026
13Renaissance Technologies LLC485,191-273,035 (-36.01%)$1 MNov 12, 2026
14Woodline Partners LP350,0000 (0.00%)$0 MNov 16, 2026
15Fiera Capital Corp315,6810 (0.00%)$0 MNov 6, 2026
16State Street Corp312,640-47,736 (-13.25%)$0 MNov 12, 2026
17XTX Topco Ltd159,492New$0 MNov 16, 2026
18Alps Advisors Inc150,167+33,071 (+28.24%)$0 MNov 3, 2026
19Jane Street Group, LLC145,666+127,323 (+694.12%)$0 MNov 12, 2026
20Persistent Asset Partners Ltd126,943New$0 MNov 13, 2026
21Goldman Sachs Group Inc124,643-36,678 (-22.74%)$0 MNov 16, 2026
22Quadrature Capital Ltd109,026New$0 MNov 13, 2026
23Acadian Asset Management LLC98,344New$0 MNov 9, 2026
24Invesco Ltd.73,731+10,846 (+17.25%)$0 MNov 12, 2026
25HRT Financial LP59,010New$0 MNov 13, 2026
Show all 48: investors 26 to 48
Institutional investors 26 to 48 in NovaBridge Biosciences
#InstitutionShares heldChange (shares)ValueFiled
26Geode Capital Management, LLC44,124-24,725 (-35.91%)$0 MNov 6, 2026
27Dimensional Fund Advisors LP39,009-77,332 (-66.47%)$0 MNov 4, 2026
28Tower Research Capital LLC (TRC)29,965+25,639 (+592.67%)$0 MNov 16, 2026
29Squarepoint Ops LLC23,551-2,917 (-11.02%)$0 MNov 9, 2026
30BNP Paribas Financial Markets20,733-8,103 (-28.10%)$0 MNov 12, 2026
31Nations Financial Group Inc, /ia/ /adv20,575New$0 MNov 5, 2026
32China Universal Asset Management Co., Ltd.20,480+2,616 (+14.64%)$0 MOct 28, 2026
33Jpmorgan Chase & Co19,428-62,128 (-76.18%)$0 MNov 12, 2026
34Group One Trading LLC15,553+15,410 (+10776.22%)$0 MNov 10, 2026
35Susquehanna International Group, LLP14,839-13,700 (-48.00%)$0 MNov 16, 2026
36Bronte Capital Management Pty Ltd.11,1920 (0.00%)$0 MNov 12, 2026
37Barclays PLC10,198-268,821 (-96.35%)$0 MNov 6, 2026
38Freestone Capital Holdings, LLC10,0000 (0.00%)$0 MNov 9, 2026
39Police & Firemen's Retirement System of New Jersey8,521New$0 MNov 9, 2026
40Mirae Asset Global Investments Co., Ltd.5,736+716 (+14.26%)$0 MOct 29, 2026
41Citigroup Inc3,033+343 (+12.75%)$0 MNov 4, 2026
42GF Fund Management Co. LTD.2,588+211 (+8.88%)$0 MOct 26, 2026
43PNC Financial Services Group, Inc.2,0000 (0.00%)$0 MNov 6, 2026
44SBI Securities Co., Ltd.1,070+995 (+1326.67%)$0 MOct 22, 2026
45Caitong International Asset Management Co., Ltd177-30,104 (-99.42%)$0 MOct 29, 2026
46Strategic Financial Concepts, LLC75New$0 MNov 16, 2026
47Rhumbline Advisers330 (0.00%)$0 MNov 10, 2026
48Eurizon Capital SGR S.p.A.10 (0.00%)$0 MNov 6, 2026

Mutual funds holding NovaBridge Biosciences#

10 funds hold shares worth $2 M. Since their previous reports 4 added shares and 6 sold, selling $0 M net.
Mutual funds holding NovaBridge Biosciences
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors591,381$1 M—0.01%+9.6%Jun 30, 2026
🇺🇸 State Street SPDR Portfolio Emerging Markets ETFSSGA Funds Management, Inc.297,847$1 M—<0.01%−1.9%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC68,849$0 M—<0.01%+21%May 31, 2026
🇺🇸 State Street SPDR S&P Emerging Markets Small Cap ETFSSGA Funds Management, Inc.48,319$0 M—0.01%−6.8%Jun 30, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP26,330$0 M—<0.01%+25%Jul 31, 2026
🇺🇸 Emerging Markets Core Equity 2 PortfolioDimensional Fund Advisors LP20,035$0 M—<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR S&P China ETFSSGA Funds Management, Inc.14,210$0 M—<0.01%−3.8%Jun 30, 2026
🇺🇸 Emerging Markets Social Core Equity PortfolioDimensional Fund Advisors LP15,130$0 M—<0.01%−35%Jul 31, 2026
🇺🇸 Emerging Markets Sustainability Core 1 PortfolioDimensional Fund Advisors LP9,306$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC5,100$0 M—<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at NovaBridge Biosciences#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$663 K
3 purchases, 1 insider
Sold, 12 months
$154 K
7 sales, 3 insiders
Net, 12 months
$509 K
open market only
Insiders on file
6
since
$577 K-$86 K$0Apr 2026: bought $577 K (1 trades), sold $0 (0 trades)Apr 26May 2026: bought $0 (0 trades), sold $43 K (1 trades)MayJun 2026: bought $0 (0 trades), sold $19 K (2 trades)JunJul 2026: bought $0 (0 trades), sold $4 K (1 trades)JulAug 2026: bought $0 (0 trades), sold $3 K (1 trades)AugSep 2026: bought $0 (0 trades), sold $86 K (2 trades)SepNov 2026: bought $86 K (2 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
NovaBridge Biosciences: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mark Arnold HaglerChief Commercial OfficerBuy+184,000$0.381$70 K460,000Form 4
filed Mark Arnold HaglerChief Commercial OfficerBuy+46,000$0.343$16 K276,000Form 4
filed Ian Ying WooDirectorOption exercise+13,271——13,271Form 4
filed Phillip Andrew DennisChief Medical OfficerSell-8,209$0.710$6 K173,427Form 4
filed Phillip Andrew DennisChief Medical OfficerOption exercise+23,695——181,636Form 4
filed Sean Wuxiong CaoChief Bus. Development OfficerSell-107,978$0.740$80 K266,467Form 4
filed Sean Wuxiong CaoChief Bus. Development OfficerOption exercise+235,136——270,209Form 4
filed Sean Wuxiong CaoChief Bus. Development OfficerOption exercise+104,236——374,445Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: NovaBridge Biosciences#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.6 M
1.3% of shares · 6.89 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-10-16 20:01 UTC, code T3, resumed 20:25 UTC

Fails to deliver

  • : 44,124 shares at $1.21
  • : 26,125 shares at $1.33
  • : 100 shares at $1.40
  • : 100 shares at $1.36
  • : 98 shares at $1.36

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

NovaBridge Biosciences scorecard#

Passes 1 of the 8 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.21 vs -0.12Diluted EPS -0.21 in fiscal 2025 against -0.12 the year before (report's currency).
    • ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against $72 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-21.4%-21.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities8.1×Current ratio 8.09 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year18.0%Diluted shares up 18.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

NovaBridge Biosciences: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

NovaBridge Biosciences: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025 · USDFY 2024to Dec 31, 2024 · USDFY 2023to Dec 31, 2023 · USDFY 2022to Dec 31, 2022 · USDFY 2021to Dec 31, 2021 · CNYFY 2020to Dec 31, 2020 · CNYFY 2019to Dec 31, 2019 · CNYFY 2018to Dec 31, 2018 · CNYFY 2017to Dec 31, 2017 · CNY
Income statement
Revenue——0.6r−1.6r881,543305412
Cost of revenue———3.94600——
Research and development632221r23r1,213985840426267
General and administrative313028r29r9004026556625
Operating expenses94517352—————
Operating income−94−51−72−53—————
Interest and finance income7.67.59.3r5.0r2124314.60.9
Interest expense and finance costs——0.10.001.03.0125.6
Share of profit of associates—−1.0−11r−65r−368−1090——
Other non-operating income (expense)−1.7−4.7−8.1r−28r83413−20−171.5
Income before tax−88−50−82r−141r−2,335483−1,452−401−298
Income tax0000.1r−3.21201.7—
Income from continuing operations−46−50−82r−141r−2,071156−1,465−439−281
Income from discontinued operations027−126−230—————
Net income including minority interests−88−22−208——————
Minority interests' share of net income−42————————
Net income attributable to shareholders−46−22−208r−371r−2,332471−1,452−403−298
Earnings per share, basic-0.21-0.12-1.09r-1.96r-13.353.51-201.19-61.70-51.93
Earnings per share, diluted-0.21-0.12-1.09r-1.96r-13.353.00-201.19-61.70-51.93
Shares, weighted average (basic)2201871911901751347.46.5—
Shares, weighted average (diluted)2201871911901751577.46.55.7
Balance sheet
Cash and cash equivalents21168292r343r3,5244,7591,1371,588413
Short-term investments0.210520r347533232——
Receivables———033130———
Inventory———0270———
Other current assets6.73.32.5r1219119513689—
Current assets218177330r5264,7825,3441,3612,037—
Property, plant and equipment0.10.21.8r8.846253028—
Right-of-use (leased) assets2.83.63.8r9.21131516——
Goodwill———24163163163163—
Other intangible assets——1717120120149149—
Investments in associates——1.74.5352665———
Total assets261213369r5915,6016,3341,7382,376—
Accounts payable177.5r7.8r10259356127468—
Current liabilities278.558r110624576588346—
Lease liabilities (non-current)2.23.13.3r4.7825.57.5——
Total liabilities3012126r1691,042707668416—
Retained earnings−1,332−1,286−1,264r−995−4,355−2,023−2,494−1,014—
Shareholders' equity231201243r418r4,5605,627−2,035−955−300
Minority interests————————306
Total liabilities and equity261213369r5915,6016,3341,7382,376—
Shares outstanding2651871861911841658.48.4—
Cash-flow statement
Depreciation and amortization—0.30.5r0.2r14139.86.71.6
Share-based compensation6.0−1.910r13r6094933673.57.0
Cash from operating activities−21−53−184−160−973434−868−281−252
Capital expenditure−0.0−0.0−0.2r−2.1r−30−8.0−12−14−20
Cash from investing activities105−1361466−727−2022129.5−158
Cash from financing activities58−0.31.16.15943,4401531,480759
Exchange-rate effect on cash————−129−1071560−0.1
Change in cash142−242−165r−77r−1,2353,565−4881,268349
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
NovaBridge Biosciences🇨🇳$177 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2020
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at NovaBridge Biosciences? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show NovaBridge Biosciences's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about NovaBridge Biosciences? Suggest a correction